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Endothelin-1 (ET-1) is a potent vasoconstrictor pep-
tide originally isolated and purified from the condi-
tioned medium of cultured porcine aortic endothelial
cells [1], and it has been shown to process a wide
spectrum of biologic activity in the kidneys [2].
Recent studies indicate that ET-1 may also play an
important role in glomerular diseases [3]. ET-1 induces
mesangial cell proliferation and the production of
extracellular matrix [4]; both are important in the
pathogenesis of glomerulosclerosis.
Antisense oligonucleotide (AON) is usually a single-
stranded synthetic nucleic acid polymer consisting of
15–25 nucleotides, and was initially used for research.
Their sequence-specific (antisense) effects are due to
the hybridization with the target mRNA in a sequence-
dependent complimentary manner. AON can be used
to disrupt gene function in a variety of in vitro culture
systems and in vivo, and they have proven potential
in clinical use [5]. AON as therapeutic agents was
proposed earlier in the 1970s when the antisense strat-
egy was initially developed. AONs have been applied
to modern molecular pharmacology. In the emerging
or expanding areas of therapeutic intervention, tran-
scription and translation are the target events of inter-
est for modifying gene expression [6]. The direct effect
of ET-1 AON on glomerular mesangial cells, how-
ever, is not clear. In this study, we observed the direct
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Antisense oligonucleotide (AON) has been applied to modern molecular pharmacology. We have
previously demonstrated that angiotensin-II (Ang-II) is an active stimulator of endothelin-1 (ET-1)
production in glomerular mesangial cells. This study was designed to investigate the specific effect
of ET-1 AON on inducing proliferation of cultured rat mesangial cells stimulated with Ang-II. ET-1
was measured by radioimmunoassays. The results were: (1) Ang-II enhanced ET-1 production of
mesangial cells; (2) ET-1 production of mesangial cells was significantly suppressed by ET-1 AON,
and this production was not affected by either ET-1 sense or scramble oligonucleotide in different
concentrations; (3) Ang-II increased [3H]-thymidine uptake of mesangial cells, which was sup-
pressed to 25% by ET-1 AON but not by ET-1 sense or scramble oligonucleotide. Our results indicate
that ET-1 AON effectively suppresses the ET-1 production and the Ang-II-stimulated proliferation
of mesangial cells, and therefore may offer treatment for proliferative glomerulonephritis.
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effects of specific ET-1 AON on ET-1 production and
[3H]-thymidine uptake of cultured rat glomerular
mesangial cells stimulated with angiotensin-II (Ang-
II), the important vasoactive peptide involved in the
formation of glomerulosclerosis.
MATERIALS AND METHODS
Culture of mesangial cells
Mesangial cells were isolated and cultured from rat
renal glomeruli according to the methods described
previously [7]. Briefly, glomeruli were harvested from
six to eight male Sprague-Dawley rats (150–200g) by
sieving the renal cortices, which were then digested
with 0.25% trypsin and 0.05% collagenase. The digested
glomeruli were incubated at 37°C in RPMI 1640
medium containing 20% fetal calf serum (FCS), peni-
cillin (100 U/mL), streptomycin (100 μg/mL) and
insulin (0.6 U/mL). After 2–3 weeks, mesangial cells
appeared and were characterized. On phase contrast
microscopy, the cells were stellate or spindle shaped in
appearance, and in postconfluent culture they piled and
formed small nodules. The nodules were sensitive to
mitomycin C, but not to aminonucleoside of puromycin,
and they contracted in response to Ang-II. In addition,
the cells failed to stain for Ia and leukocyte common
antigen. The cell passage was performed every 4–6
days. Cells were starved by incubation in a medium
containing 0.5% FCS for 24 hours before adding 
the reagents. The animal experiment was approved
by the animal committee of Kaohsiung Medical
University.
Experimental protocol
ET-1 production of cultured rat glomerular mesan-
gial cells was measured. Mesangial cells were stim-
ulated with Ang-II after obtaining a dose-response
curve [8]. Cells were also preincubated with ET-1
AON for 24 hours before stimulation with Ang-II.
Ang-II was purchased from Sigma Chemical Co. 
(St Louis, MO, USA).
Thymidine uptake
Mesangial cells were brought to confluent density,
trypsinized, and counted. The medium was aspirated
and the cells were washed twice with Dulbeccos-PBS
and treated with 1 mL of 0.2% trypsin–0.02% EDTA
solution for 10 minutes at 37°C. Cells were then 
resuspended in RPMI 1640 containing 20% FCS and
were adjusted to a concentration of 2 × 104 cells/mL.
An aliquot of 200 μL of cells was placed in each of 96
well plates. The plates were cultured for 48 hours in a
5% CO2 humidified atmosphere at 37°C, and then the
medium was replaced with RPMI containing 0.5%
FCS. After adding Ang-II for 3 hours, the plates were
pulsed with 0.5 μCi of [3H]-labeled thymidine per
well for 18 hours [9]. The cells were harvested onto
glass fiber filters, and washed with distilled water
using a semiautomatic cell harvester. The incorpo-
rated radioactivity was counted with a β-scintillation
counter. All assays were performed in triplicate.
Radioimmunoassay (RIA) for ET-1
The ET-1-like immunoreactivity of supernatant was
determined by a specific ET-1 RIA (Peninsula Labora-
tories, Inc., Belmont, CA, USA) after extraction. The
supernatant was applied to a Sep-Pak C18 cartridge
(Waters Associates, Milford, MA, USA) and eluted
with 5 mL of 60% acetonitrile in 0.1% trifluoroacetic
acid. The eluate was lyophilized and reconstituted
for RIA. The antibody used cross-reacted with ET-1
(100%), big ET-1 (17%), ET-2 (7%) and ET-3 (7%) and
did not react with Ang-II, vasoactive intestinal peptide
or α-ANP 1–28. The recovery rate of ET-1, extracted
through a Sep-Pak C18 column by adding radiolabeled
ET-1 to the medium, was 61.2 ± 1.2%. The sensitivity
for ET-1 RIA was 0.4 pg/tube, and the 50% intercept
was 20 pg/tube. The intra- and interassay coeffi-
ciency of variation was 9.7% and 10.5%, respectively,
over a range of concentration between 0.1 and 64 pg/
tube [10].
Preparation of ET-1 AON
Mesangial cells were grown to 80% confluence on 
coverslips and transiently transfected with either anti-
sense or scrambled phosphorothioate-modified oligo-
nucleotide according to the manufacturer’s instructions
(Genosys Company, Woodlands, TX, USA). The se-
quence was as follows: 5′-ATCACGGGAAAATAATC-
CAT-3′. The sense oligonucleotide had the sequence
5′-ATGGATTATTTTCCCGTGAT-3′, and the scramble
oligonucleotide had the sequence 5′-ATACACTGGA-
AGAATAATCT-3′. Cells were preincubated for 24
hours with the same concentration of ET-1 antisense,
sense, and scramble oligonucleotides, and the super-
natants were collected after stimulation with 2% FCS
for 48 hours.
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Statistical analysis
Data were presented as mean±SEM. One way ANOVA
and unpaired t test were used to compare the difference
between each pair, and p < 0.05 was considered to be
statistically significant.
RESULTS
Effects of Ang-II on ET-1 production
The ET-1 production of mesangial cells was signifi-
cantly enhanced after stimulation with both Ang-II
(102.1 ± 3.2 pg/mL, p < 0.01) and 2% FCS (110.3 ±
5.8 pg/mL, p < 0.001 compared to controls 87.9 ±
2.9 pg/mL) (Figure 1).
Effects of ET-1 AON on ET-1 protein
production
ET-1 protein production was significantly suppressed
by ET-1 AON at the concentrations of 1×10−5 M
(9.8±0.9pg/mL, p<0.001), 2×10−6 M (12.1±1.3pg/mL,
p < 0.001) and 4 × 10−7 M (10.7 ± 1.8 pg/mL, p < 0.001
compared to that stimulated with 2% FCS, 37.5 ±
5.3 pg/mL). The amount of ET-1 production was not
affected by either ET-1 sense or scramble oligonucle-
otides in different concentration (Figure 2).
Effects of ET-1 AON on Ang-II-stimulated
thymidine uptake
The [3H]-thymidine uptake of mesangial cells was
significantly enhanced by 10−7 M Ang-II (1,204 ± 75
compared to control 870 ± 52 cpm, p < 0.001). The ef-
fect was significantly suppressed by ET-1 AON at
concentrations of 10−8 M and 10−9 M (890 ± 50 and
920 ± 32 cpm, respectively, both p < 0.01 compared to
the effect of Ang-II). The effect on thymidine uptake
was not affected by either ET-1 sense or scramble oli-
gonucleotides at different concentrations (Figure 3).
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Figure 1. Effects of angiotensin-II (Ang-II, 10−7 M) and 2% fetal
calf serum (FCS) on the endothelin-1 (ET-1) production of mesan-
gial cells. The supernatants were collected after stimulation for
72 hours. Data are presented as the mean ± SEM of all three inde-
pendent experiments performed in triplicate. *p < 0.01 and †p <
0.001 compared to control (C) without stimulation.
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Figure 2. Effects of endothelin-1 (ET-1) antisense oligonucleotide (AON) on ET-1 production of glomerular mesangial cells. Cells were
preincubated for 24 hours with the same concentrations of ET-1 antisense, sense and scramble oligonucleotides, and the supernatants
were collected after stimulation with 2% fetal calf serum (FCS) for 48 hours. *p < 0.001 compared to the effect of 2% FCS only. Data
are presented as the mean ± SEM of three independent experiments performed in triplicate.
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DISCUSSION
In this study, we have demonstrated that ET-1 AON
effectively suppressed the ET-1 production and the
Ang-II-stimulated [3H]-thymidine uptake of mesangial
cells. The use of AON as therapeutic agents has become
a popular topic in both the research and the clinical
fields [11–13]. The principle of antisense technology is
the sequence-specific binding of an AON to target
mRNA, resulting in the prevention of gene translation
and the modulation of gene expression involved in
the pathogenesis of diseases. There has been a rapid
increase in the number of antisense molecules pro-
gressing past Phase I, II and III clinical trials in recent
years [14].
In studies with AON, researchers must differentiate
between the desired sequence-specific inhibition of
the targeted mRNA from the undesired sequence-
related and non-sequence-related effects, in order 
to choose and design appropriate therapeutic oligo-
nucleotides. Negative controls serve to rule out the 
possibility that the effects of AON are caused by non-
sequence-specific mechanisms, while positive controls
provide additional evidence that a true antisense effect
is the reason for the biologic effects. Usually, a com-
bination of at least two different controls is recom-
mended. In this study, we used sense control which
has a sequence complementary to that of the AON, and
we also used scrambled control which is generated by
mixing up the AON bases in a randomized manner.
Similar effects of ET-1 AON was not seen in sense or
scramble oligonucleotides.
Our study demonstrated that Ang-II is an active
stimulant for the proliferation of glomerular mesan-
gial cells. Ang-II is known as a critical factor for the
progression of chronic renal diseases [15]. Ang-II con-
tributes to the inflammatory process in glomerular
disorders, facilitating the migration of mononuclear
cells to the glomeruli and ultimately participates in
the fibrotic process. We have also demonstrated that
the effects of Ang-II on mesangial cells were partly
mediated by ET-1, another vasoactive peptide in-
volved in glomerular diseases [3]. ET-1 had been
found to induce the proliferation of mesangial cells
and the production of extracellular matrix [4], both
are similar to the action of Ang-II and therefore may
explain the possible mechanisms for the effect of Ang-II
on mesangial cells. We have also demonstrated that
ET-1 AON suppresses ET-1 production, while sense
and scramble do not have similar effects. Therefore,
ET-1 AON may also be used in the treatment of related
disorders.
In conclusion, we have demonstrated that ET-1
AON effectively suppressed the ET-1 production and
the Ang-II-stimulated proliferation of mesangial cells.
Therefore, ET-1 AON may be used in the treatment 
of ET-1 and Ang-II-related glomerular disorders in
the future.
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Figure 3. Effects of endothelin-1 (ET-1) antisense oligonucleotide (AON) on [3H]-thymidine uptake of glomerular mesangial cells stimu-
lated with angiotensin-II (Ang-II). Cells were preincubated for 24 hours with the same concentrations of ET-1 antisense, sense and scramble
oligonucleotides, and then stimulated with Ang-II (10−7 M) before adding [3H]-thymidine. *p < 0.001 compared to control; †p < 0.01
compared to the effect of Ang-II only. Data are presented as the mean±SEM of three independent experiments performed in quadriplicate.
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